News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

|Articles|May 2, 2004

Pharmaceutical Technology

Pharmaceutical Technology-05-02-2004
Volume 28
Issue 5

FDA Eyes Manufacturing Innovation to Boost Drug Development

Author(s)Jill Wechsler

New technologies, along with changes in FDA oversight, may provide a critical path to make more new drugs available more quickly to patients.

External Link - article-94552.pdf

Articles in this issue

about 22 years ago

Article

Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology

about 22 years ago

Article

An LC Method for the Separation and Determination of Ethynodiol Diacetate and Ethinyl Estradiol in Tablets

about 22 years ago

Article

In The Spotlight-May 2004

about 22 years ago

Article

Prepare for Bar Coding

about 22 years ago

Article

Validation and Compliance: Software Systems Prepare Manufacturers for Com(PAT)ibility

about 22 years ago

Article

aaiPharma Situation Underscores The Need for Due Diligence

about 22 years ago

Article

Excipient Functionality

about 22 years ago

Article

Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology

about 22 years ago

Article

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Scientist working in biosimilars development with futuristic medical technology and digital interface elements | Image Credit: ©KHAN VECTOR CO. -stock.adobe.com

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

ByKimberly Salgado

June 3rd 2026

Ebola virus outbreak biosecurity interface in medical laboratory, infectious disease prevention healthcare emergency, quarantine containment diagnostics vaccine research, public health | Image Credit: ©Sapra -stock.adobe.com

EMA Collaborates with African Regulators on Ebola Treatments

BySusan Haigney

June 3rd 2026

Matt Meyer, Governor, State of Delaware

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision

ByZachary Zubulake,Christopher Cole

June 3rd 2026

Adeno-associated virus. AAV virus genome. Adenoviral pneumonia, arthritis, bronchitis, hepatitis, cystitis. Adenovirus as vectors for gene therapy. Genetic material transmission to cell. Biotech 3D | Image Source: ©Corona Borealis -stock.adobe.com

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

June 3rd 2026

Single use syringe for injection treatment on medical table with vials of liquid drug doses flu shots at background. Vaccination or immunization care concept | Image Credit: ©Mikhailov Studio -stock.adobe.com

USP Publishes Biologics Standards for Public Comment

BySusan Haigney

June 2nd 2026

Trending on Pharmaceutical Technology

Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision

Generic GLP-1s Enter Canadian Market